熊去氧胆酸
代谢物
肾
肠道菌群
过氧化物酶体
化学
下调和上调
脂肪酸
药理学
脂肪肝
医学
肾脏疾病
β氧化
内分泌学
肾损伤
内科学
前药
脂质代谢
真细菌
肾小管病变
生物化学
胆固醇
作者
Ming Xie,Jun Zheng,Yu Yao,Qishen Yang,Zhipeng Zhou,Jingwen Xue,Benlin Wang,Yi‐Feng Qiu,Zhangrui Zhu,Qi Sun,Xinhang Shi,Wentai Shangguan,Leqian Li,Zhipeng Zou,Jie Zhao,Peng Wu
标识
DOI:10.1016/j.xcrm.2025.102373
摘要
Renal ischemia-reperfusion injury (IRI) is a common complication of renal surgery that currently lacks effective prevention or treatment strategies. The gut microbiota and their metabolites are closely associated with kidney injury. However, the exact mechanisms underlying this link are unclear. Here, we find that renal IRI reduces ursodeoxycholic acid (UDCA), a metabolite of Eubacterium limosum (E. limosum), in mice cecal content and serum. Conversely, supplementation with either E. limosum or UDCA prevents these mice from IRI. Mechanistically, UDCA directly binds and activates peroxisome proliferator-activated receptor-gamma (PPARγ) to increase fatty acid oxidation, inducing ATP production and reducing lipid accumulation in proximal tubular epithelial cells, ultimately protecting the kidney against IRI. Importantly, while renal IRI in patients markedly lowers their serum UDCA, patients with higher pre-IRI UDCA or E. limosum level develop less severe IRI. Collectively, our findings highlight the rationale of using UDCA and E. limosum for the prevention or treatment of renal IRI.
科研通智能强力驱动
Strongly Powered by AbleSci AI